Skip to main content

Table 4 Gain in response rate vs gain in survival for anticancer drugs approved by FDA 2002-2012

From: Fool’s gold, lost treasures, and the randomized clinical trial

Drug Tumor type Gain in response rate p Gain in OS, months p
Oxaliplatin [156, 171] Colorectal 48% vs 32% 0.006 5.6 <0.001
Pemetrexed [157] Mesothelioma 41.3% vs 16.7% <0.0001 2.8 0.02
Bevacizumab [152] Colorectal 44.8% vs 34.8% 0.004 4.7 <0.0001
Gemcitabine [158] Breast 41.4% vs 26.2% 0.0002 2.8 0.0489
Erlotinib [37] Pancreas 8.6% vs 8% NSa 0.33 0.038
Docetaxel [159] Gastric 37% vs 25% 0.01 1.9 <0.001
Topotecan [160] Cervix 27% vs 13% 0.004 2.9 0.017
Bevacizumab [153] Colorectal 22.7% vs 8.6% <0.0001 2.1 0.0011
Gemcitabine [161] Ovary 42.7% vs 30.9% 0.0016 0.7 0.83b
Bevacizumab [151] NSCLC 35% vs 15% <0.001 2 0.003
Docetaxel [162] Head and Neck 68% vs 54% 0.006 3.3 0.02
Lapatinib [163] Breast 22% vs 14% 0.09 NAc 0.72 b
Lapatinib [164] Breast 23.7% vs 13.9% 0.017 0.3 0.18 b
Temsirolimus [165] Renal 8.1% vs 4.8% NS 1.1 0.70 b
Ixabepilone [166, 167] Breast 35% vs 14% <0.0001 1.8 0.19 b
Bevacizumab [154, 155] Renal 31% vs 13% 0.0001 2.0 0.33 b
Lapatinib [168] Breast (Her-2/neu +ve) 28% vs 15% 0.021 1.0 0.11 b
Trastuzumab [169] Gastroesophageal 47% vs 35% 0.0017 2.7 0.0046
Cetuximab [170] Head and neck 36% vs 20% <0.001 2.7 0.04
  1. a. NS: not significant.
  2. b. PFS differed significantly.
  3. c. NA: not available.